ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM: Abstract Number: 1788

Memory B Cell Activation and Dysregulation in Systemic Lupus Erythematosus

SLE – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 2330

Mental Health, Sex, and Comorbidities as Determinants of Recalcitrant PsA

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2479

Mepolizumab Treatment Decreased Oral Corticosteroid Use and Improved Clinical Response, Control Status, and Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis: Results up to 24 Months from a Large Network of US Allergy Practices

Vasculitis – ANCA-Associated Poster III

10:30AM-12:30PM: Abstract Number: 2524

Metabolite Profiling of Saliva for the Discrimination of Behcet’s Disease, Sjogren’s Syndrome, and Recurrent Aphthous Stomatitis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

10:30AM-12:30PM: Abstract Number: 1774

Metabolomics and Lipidomics in Juvenile Localized Scleroderma

Pediatric Rheumatology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 2240

Methotrexate Use Influenced the Effect of Inflammation on Cardiovascular Risk Differently in Anticitrullinated Protein Antibody Negative and Positive Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2213

Microvascular and Macrovascular Endothelial Dysfunction in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2189

Migratory Arthritis in Children: What Besides Rheumatic Fever?

Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 1772

Modeling and Predicting HLH Through Measurement of Immune Synapse Duration, Cytokine Production, and Target Cell Death

Pediatric Rheumatology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 1810

Modulation of Type I Interferon Signaling by Anifrolumab Alters the Spatial Immune Landscape in Cutaneous Lupus Erythematosus

SLE – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 1782.5

Monocytes from HLA B27 Positive Enthesitis Related Arthritis Patients Are More Activated Than HLA B27 Negative Patients

Pediatric Rheumatology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 2297

Mortality and Its Predictor Variables in Patients with Sjögren Disease: Data from SjögrenSER-Pros Prospective Registry

Sjögren's Syndrome – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 2493

Mortality in Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis: Study from a Single University Hospital

Vasculitis – ANCA-Associated Poster III

10:30AM-12:30PM: Abstract Number: 1762

Multi-omic Analysis Defines Heterogeneous and Cell Specific Type I Interferon Signalling in Juvenile-onset SLE Patients Associated with Biomarkers of Cardiovascular Risk

Pediatric Rheumatology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 1789

Multi-omic Profiling Identifies Pathogenic Pro-inflammatory Human Monocytes/Macrophages in Systemic Lupus Erythematosus

SLE – Etiology & Pathogenesis Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].